31.6 C
Vientiane
Sunday, June 8, 2025
spot_img
Home Blog Page 31

Creative Primary School and Creative Primary School’s Kindergarten Celebrate 40th Anniversary with Successful Open Day


HONG KONG SAR – Media OutReach Newswire – 2 June 2025 – On 24 May 2025, Creative Primary School (CPS) and Creative Primary School’s Kindergarten (CPSKG) held a grand open day to celebrate their 40th anniversary, welcoming guests, parents, alumni, and community members. Nestled in the prestigious educational hub of Oxford Road, Kowloon Tong, Hong Kong, China, these two institutions have, for four decades, served as distinguished private schools, delivering exceptional education and nurturing generations of outstanding students.

Established in 1985, CPS and CPSKG have championed holistic education, aligning with Hong Kong's 2000 education reforms emphasizing critical thinking, character, and lifelong learning.
Established in 1985, CPS and CPSKG have championed holistic education, aligning with Hong Kong’s 2000 education reforms emphasizing critical thinking, character, and lifelong learning.

Student-Led Exhibitions and Performances
The day featured the IB PYP Units of Inquiry Exhibition, student-led research presentations, workshops, and performances, reflecting the school’s commitment to holistic education. Parents explored the campus guided by students, while alumni reconnected with teachers. Special guests from the International Alliance for Invitational Education (IAIE) attended, highlighting the school’s “Care, Respect, and Trust” culture.

CPSKG’s “Sky of Growth” exhibition showcased child-led learning across subjects like English, Chinese, science, robotics, and art, embodying the philosophy of “Inspiring curiosity, nurturing explorers.” Teachers guided students in constructing knowledge through research, fostering critical thinking and lifelong learning. Parents admired the children’s creativity, witnessing the student-centered curriculum in action.

An alumnus shared: “Returning to my alma mater let me see the school’s ongoing innovation.”

Forty Years of Excellence
Established in 1985, CPS and CPSKG have championed holistic education, aligning with Hong Kong’s 2000 education reforms emphasizing critical thinking, character, and lifelong learning. With the later addition of Creative Secondary School (CSS), the institution now offers a seamless 3–18 education, blending Eastern and Western pedagogy.

Global Recognition and Future Vision
As an IB World School, the institution emphasizes inquiry-based learning, with trilingual (English, Chinese, Putonghua) foundations in early years and English-medium secondary education. Its “Inviting School Award” from IAIE underscores its nurturing environment.

Mr. Victor Fong, Open Day Committee Chairman and School Supervisor, noted: “In an era of AI and rapid change, we remain committed to cultivating adaptable, compassionate leaders.” He thanked faculty and parents for their support.

The open day celebrated past achievements while marking a new chapter. The school invites the community to join its journey—inspiring future generations of learners.

Factual Highlights of the Creative Schools Continuum
Three Schools ‧ One Philosophy ‧ One Continuum

  • The motto of Creative Schools Continuum is “Nurture Future Minds * Build Boundless Capacity”, highlighting the continuum’s foresights and insights of quality education and our commitments to our students and parents.
  • Creative Primary School and Creative Secondary School are award-winning “Inviting Schools”. The award recognizes the schools’ commitments to providing an exceptionally caring, trusting, respectful and positive learning environment for its students and staff.
  • As International Baccalaureate (IB) World Schools, Creative Primary and Creative Secondary Schools offer the IB Primary Years Programme (IB PYP), IB Middle Years Programme (IB MYP) respectively.
  • Creative Secondary School also offers the Hong Kong Diploma of Secondary School Examination (HKDSE) course in parallel with the IB Diploma Programme (IBDP) as pathways to university entrances.

Hashtag: #CSS #CPS #CPSKG #CreativeSchoolsContinuum

The issuer is solely responsible for the content of this announcement.

Dilon Technologies Partners with Australian Allografts as Exclusive Distributor for Navigator 2.0™ Gamma Localization System in Australia

NEWPORT NEWS, Va., June 2, 2025 /PRNewswire/ — Dilon Technologies is pleased to announce the partnership of Australian Allografts as the exclusive distributor of the Navigator 2.0™ Lymphatic Mapping System in Australia, effective immediately.

This strategic collaboration reflects Dilon Technologies’ ongoing commitment to delivering exceptional patient care through advanced medical technology. By partnering with Australian Allografts and their specialized support team, Dilon is enhancing access to the Navigator 2.0 system and reinforcing their ability to provide localized, responsive service throughout the region.

“Dilon Technologies remains steadfast in its mission to improve patient outcomes by equipping healthcare providers with precise, reliable, and user-friendly technology. The Navigator 2.0 Gamma Localization System is a critical component in breast surgery, and ensuring its continued availability is central to our dedication to clinicians and the patients they serve,” stated George Makhoul, CEO of Dilon Technologies.

In addition to the Navigator 2.0 system, Australian Allografts will also support the full portfolio of Dilon products, upholding the high standards of quality, performance, and support that healthcare providers and their patients rely on.

Logo – https://laotiantimes.com/wp-content/uploads/2025/06/dilon_technologies_logo.jpg

Peacock 1953 Aircraft Hand Watch: Heritage Meets Horological Innovation in a Tribute to China’s Watchmaking Pioneers

SHENZHEN, China, June 2, 2025 /PRNewswire/ — Peacock Watch today launches the Peacock Perfection Classic 1953 “Aircraft Hand”, a limited-edition timepiece that marries mid-century Chinese watchmaking heritage with 21st-century craftsmanship. Inspired by the original “Aircraft Hand” of the 1970s Hongqi (Red Flag) commemorative watch produced by Liaoning Watch Factory, this model revives a symbol of national pride and technological triumph with modern refinement and rare flame-blued titanium hands.

Peacock Unveils Perfection Classic 1953 "Aircraft Hand" Vintage Watch
Peacock Unveils Perfection Classic 1953 “Aircraft Hand” Vintage Watch

Heritage & Inspiration

The year 1953 marked a turning point in the People’s Republic of China—an era of rebuilding and renewed peace. Peacock commemorates that moment with a watch that channels vintage soul through design cues first seen in the Hongqi series of the 1970s, when Liaoning Watch Factory (now Peacock) celebrated the successful launch of Dongfanghong-1, China’s first satellite, on 24 April 1970. The original “Aircraft Hand”—a sweeping, aircraft-shaped seconds hand—became an emblem of hope and progress, earning cult status among collectors.

The “Red Flag Hand” & Flame-Blued Titanium

Peacock elevates the vintage motif into the “Red Flag Hand”, accentuating its curves and sharpening its profile to evoke both aviation and national symbolism. Each hand undergoes hand-flame-bluing on titanium alloy—a notably demanding technique that involves heating the metal to 550–600 °C over a naked flame, producing a shifting blue-violet iridescence through natural oxidation, not paint. Unlike steel—which blues at ~300 °C—titanium requires much higher temperatures, making the process exceptionally rare and difficult.

Four Shades of Triumph

Echoing the journey from struggle to victory, the collection introduces four dial hues—CANG XIAN, XI, SHU – each named for the tones of water, frost, dawn, and sunrise. These colors symbolize resilience, silent strength, renewed promise, and radiant glory, respectively, weaving narrative depth into every glance at the dial.

Masterful Details

  • Five-Facet Dauphine Hands: Hour and minute hands shaped via Peacock’s proprietary five-facet cutting technique (100+ precision cuts), with brushed tops and mirror-polished bevels for optimal legibility and luminous interplay.
  • Custom Calligraphic Numerals: Arabic indices inspired by Zan Ke engraving and classical brush strokes, engraved and brushed on the dial for tactile depth and cultural resonance.
  • Narrative Date Window: On the 19th, the aperture reveals Yalu River Bridge line art; on the 27th, a peace dove emerges—subtle tributes to the brand’s Dandong heritage and a universal message of hope.

Movement & Finishing

The in-house PAX6910 automatic caliber channels Swiss haute horlogerie traditions—featuring Geneva stripes, perlage, polished anglage, chamfered bridges, and a gold-toned rotor—while offering five-position adjustment and robust reliability.

Case & Strap

Encased in 904L aerospace-grade steel, the 38.5 mm case (9.4 mm thick) balances brushed and mirror finishes. Bugle Horn lugs symbolize courage, and a raised sapphire crystal ensures crystal-clear legibility. Paired with a hand-stitched Novonappa calfskin strap—stitched in waxed thread and engraved “1953.7.27”—this watch is built to last as long as its legend.

Peacock Watches International official website https://peacockwatches.com/

Availability & Press Inquiries
 The Peacock Perfection Classic 1953 “Aircraft Hand” is available now in a limited production run. For high-resolution imagery, review samples, or interview requests, please contact: vip@peacockwatches.com

CARsgen Presents Research Results on Satri-cel in The Lancet and at the 2025 ASCO Annual Meeting

SHANGHAI, June 2, 2025 /PRNewswire/ — CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the results of the pivotal Phase II clinical trial in China (CT041-ST-01, NCT04581473) investigating satricabtagene autoleucel (“satri-cel”, CT041) (a Claudin18.2-specific autologous CAR T-cell product candidate) in patients with Claudin18.2-positive, advanced gastric/gastroesophageal junction cancer refractory to at least two prior lines of treatment, have been published in The Lancet and were orally presented at the 2025 ASCO Annual Meeting. Further details have been posted on the corporate website https://www.carsgen.com.

The article in The Lancet was titled “Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician’s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial”. Full article available at: https://doi.org/10.1016/S0140-6736(25)00860-8.

The oral presentation at the 2025 ASCO Annual Meeting (Abstract 4003) was titled “Claudin18.2-specific CAR T cells (Satri-cel) versus treatment of physician’s choice (TPC) for previously treated advanced gastric or gastroesophageal junction cancer (G/GEJC): Primary results from a randomized, open-label, phase II trial (CT041-ST-01)”.

Professor Lin Shen from Beijing Cancer Hospital, the principal investigator of this study, said, “The CT041-ST-01 trial represents the world’s first randomized controlled clinical study of CAR-T cell therapy for solid tumors. In patients with heavily pretreated, advanced gastric/gastroesophageal junction cancer who have extremely limited treatment options and poor prognosis, satri-cel has demonstrated breakthrough efficacy with significant clinical benefits, including much improved progression-free survival (PFS), overall survival (OS), and tumor response rates. This brings new hope to patients with otherwise medically untreatable conditions. We are further exploring satri-cel’s potential in adjuvant settings and as first-line sequential therapies, aiming to intervene earlier in the disease course, extend patients’ survival, and ultimately pursue potential cures.”

Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive Officer, and Chief Scientific Officer of CARsgen Therapeutics, said, “We are honored that the CT041-ST-01 study results were published in The Lancet—a premier, global medical journal—and presented at the 2025 ASCO Annual Meeting. The positive result of this randomized controlled trial marks a major milestone in solid tumor CAR-T therapy. These achievements are a testament to the whole research team’s years of dedication, and we extend our deepest gratitude to patients and their families for their trust and participation. This year, satri-cel has been granted Breakthrough Therapy Designation and Priority Review by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA) in patients who have failed at least two prior lines of therapy. We plan to submit a New Drug Application (NDA) for satri-cel to the NMPA this month and anticipate its approval as the world’s first commercially available CAR-T product for solid tumors, bringing benefits to patients.”

About Satri-cel

Satri-cel is an autologous CAR T-cell product candidate against the protein Claudin18.2 that has the potential to be the first-in-class globally. Satri-cel targets the treatment of Claudin18.2-positive solid tumors with a primary focus on G/GEJA and pancreatic cancer (PC). Initiated trials include investigator-initiated trials (CT041-CG4006, NCT03874897), a confirmatory Phase II clinical trial for advanced G/GEJA in China (CT041-ST-01, NCT04581473), a Phase Ib clinical trial for PC adjuvant therapy in China (CT041-ST-05, NCT05911217), an investigator-initiated trial for satri-cel be used as consolidation treatment following adjuvant therapy in patients with resected G/GEJA (CT041-CG4010, NCT06857786), and a Phase 1b/2 clinical trial for advanced gastric or pancreatic adenocarcinoma in North America (CT041-ST-02, NCT04404595).

Satri-cel has been granted Priority Review by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in May 2025. Satri-cel has been granted Breakthrough Therapy Designation by the CDE of China’s NMPA for the treatment of Claudin18.2-positive advanced G/GEJA in patients who have failed at least two prior lines of therapy in March 2025. Satri-cel was granted Regenerative Medicine Advanced Therapy designation by U.S. FDA for the treatment of advanced G/GEJA with Claudin18.2-positive tumors in January 2022. Satri-cel received Orphan Drug designation from the U.S. FDA in September 2020 for the treatment of G/GEJA.

About CARsgen Therapeutics Holdings Limited

CARsgen is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies to address the unmet clinical needs including but not limited to hematologic malignancies, solid tumors and autoimmune diseases. CARsgen has established end-to-end capabilities for CAR T-cell research and development covering target discovery, preclinical research, product clinical development, and commercial-scale production. CARsgen has developed novel in-house technologies and a product pipeline with global rights to address challenges faced by existing CAR T-cell therapies. Efforts include improving safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs, etc. CARsgen’s mission is to be a global biopharmaceutical leader that provides innovative and differentiated cell therapies for patients worldwide and makes cancer and other diseases curable.

Forward-looking Statements

All statements in this press release that are not historical fact or that do not relate to present facts or current conditions are forward-looking statements. Such forward-looking statements express the Group’s current views, projections, beliefs and expectations with respect to future events as of the date of this press release. Such forward-looking statements are based on a number of assumptions and factors beyond the Group’s control. As a result, they are subject to significant risks and uncertainties, and actual events or results may differ materially from these forward-looking statements and the forward-looking events discussed in this press release might not occur. Such risks and uncertainties include, but are not limited to, those detailed under the heading “Principal Risks and Uncertainties” in our most recent annual report and interim report and other announcements and reports made available on our corporate website, https://www.carsgen.com. No representation or warranty is given as to the achievement or reasonableness of, and no reliance should be placed on, any projections, targets, estimates or forecasts contained in this press release.

Contact CARsgen

For more information, please visit https://www.carsgen.com/

 

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

SAN FRANCISCO, and SUZHOU, China, June 2, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein) monotherapy and combo-therapy with bevacizumab in advanced colorectal cancer were orally presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. IBI363 demonstrated encouraging response and overall survival benefit in the context of colorectal cancer, which is typically considered an immunologically ‘cold’ tumor, supports its unique mechanism of actions (MoA) of turning “cold tumor” into “hot tumor”.

Innovent Biologics is conducting clinical studies in China, the United States, and Australia to explore the efficacy and safety of IBI363 for multiple tumor indications, including immune resistance, cold tumors, and front-line treatments. At this year’s ASCO meeting, IBI363 reported encouraging Phase 1/2 clinical data in the first three indications explored—non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma—focusing on IO-resistant and cold tumors. The data comprehensively demonstrated the breakthrough clinical outcomes of IBI363 across these indications, from robust tumor response to long-term survival benefits. These findings provide strong support of the drug’s novel mechanism of action translating effectively into clinical outcomes, and imply its potential for broader clinical development, offering new hope in areas of immunotherapy where treatment options remain limited.

PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 monotherapy and combined with bevacizumab in participants with advanced colorectal cancer: results from Phase 1 studies

Two Phase 1 studies (NCT05460767, NCT06717880) were conducted to evaluate the safety, tolerability and preliminary efficacy of IBI363 monotherapy and combined with bevacizumab in patients with advanced colorectal cancer.

IBI363 monotherapy has demonstrated breakthrough antitumor therapeutic potential, showing a significant extension of overall survival compared to data of standard-of-care therapies

  • As of the data cutoff date (Apr 7th, 2025), a total of 68 participants with advanced colorectal cancer received IBI363 monotherapy at the dose levels from 0.1 mg/kg to 3mg/kg. No patients were confirmed as microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). 86.8% of patients were microsatellite stable (MSS) or proficient mismatch repair (pMMR). 61.8% of patients had liver metastases. 63.2% of patients had previously received 3 or more lines of systemic anti-tumor treatments. 23.9% of patients had received prior immunotherapy.
  • Notably, among patients receiving monotherapy with IBI363 (n=68), with a median follow-up time of 20.1 months, the median overall survival (OS) reached 16.1 months, demonstrating a significant improvement compared to the historical data of standard treatments (ranging from 6.4 to 9.3 months1-3).
  • Subgroup analyses revealed that patients with or without liver metastasis both showed excellent overall survival (OS), indicating significant clinical benefit. The median OS were 14.4 months (with liver metastasis) and 17.0 months (without liver metastasis).
  • Among patients treated with monotherapy of IBI363 1 mg/kg every 2 weeks (Q2W) (n=22), the confirmed objective response rate (cORR) was 13.6%.

Liver metastasis
(n = 42)

without liver metastasis
(n = 26)

Total

(n = 68)

Median OS, month (95% CI)

14.4 (8.0, 18.8)

17.0 (9.9, NC)

16.1 (10.1, 18.8)

6-month OS rate, % (95% CI)

81.3 (64.6, 90.6)

80.0 (58.4, 91.1)

80.7 (68.5, 88.6)

12-month OS rate, % (95% CI)

54.8 (36.9, 69.5)

59.5 (37.8, 75.8)

56.6 (43.0, 68.1)

18-month OS rate, % (95% CI)

37.6 (21.3, 53.9)

44.8 (24.0, 63.6)

40.3 (27.2, 53.0)

OS median follow-up time, month (95% CI)

20.2 (17.9, 20.7)

20.1 (16.8, 21.7)

20.1 (17.7, 20.6)

The combination of IBI363 and bevacizumab demonstrated encouraging efficacy signals and a manageable safety profile, with excellent data on objective response rate and progression-free survival

  • As of the data cutoff date (Apr 7th, 2025), a total of 73 patients with advanced colorectal cancer received IBI363 (dose levels from 0.6 mg/kg to 3mg/kg) and bevacizumab combination therapy. No patients were confirmed as MSI-H or dMMR. 91.8% of patients were MSS or pMMR. 56.2% of patients had liver metastases. 54.8% of patients had previously received 3 or more lines of systemic anti-tumor treatments. 16.4% of patients had received prior immunotherapy.
  • In all participants treated with IBI363 in combination with bevacizumab (n=73), the cORR was 15.1% and the disease control rate (DCR) was 61.6%. With a median follow-up time of 9.9 months, the median progression free survival (PFS) reached 4.7 months. With a median follow-up time of 9.4 months, OS was not mature, with events in only 13 participants (17.8%).
  • As for the combination therapy in patients without liver metastases (n=32), the confirmed ORR was 31.3%, with a DCR of 81.3%. The median PFS reached to 7.4 months.
  • In those participants who received IBI363 at 3 mg/kg Q3W plus bevacizumab (n=31), confirmed ORR and DCR increased to 19.4% and 71.0%, respectively. The median PFS increased to 5.6 months.

IBI363 3 mg/kg Q3W +Bevacizumab

(n = 31)

Without liver metastasis
(n = 32)

Total

(n = 73)

Confirmed ORR, % (95% CI)

19.4 (7.5, 37.5)

31.3 (16.1, 50.0)

15.1 (7.8, 25.4)

DCR, % (95% CI)

71.0 (52.0, 85.8)

81.3 (63.6, 92.8)

61.6 (49.5, 72.8)

Median PFS, month (95% CI)

5.6 (2.5,6.8)

7.4 (4.1, 9.8)

4.7 (2.5,6.7)

PFS median follow-up time, month (95% CI)

8.6 (7.2, 10.2)

9.9 (7.2, 13.1)

9.9 (7.2, 13.9)

  • In terms of safety, among participants receiving monotherapy and combination therapy, 19 (27.9%) and 26 (35.6%) reported treatment-related adverse events (TRAEs) of Grade 3 or higher, respectively. The most common TRAEs were arthralgia, anemia, rash, and hypothyroidism. No new safety signals were observed, with a manageable risk-benefit profile in IBI363 alone or in combination with bevacizumab.

Tumor immune cell infiltration analysis supports the IBI363 MOA of turning “cold tumor” into “hot tumor”, demonstrating enrichment of PD1+CD25+CD8+ cells in baseline tumor tissue association with clinical efficacy

  • In baseline tumor tissues, elevated infiltration of CD8+ cells, CD25+CD8+ cells, and PD1+CD25+CD8+ cells were associated with improved clinical response to IBI363 monotherapy (partial response or stable disease). This supports the potential anti-tumor effects of IBI363 in the treatment of colorectal cancer from the perspective of its mechanism of action.

Professor Tao Zhang, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, stated: “Colorectal cancer is the third most common cancer type globally and ranks fourth in cancer-related mortality4. About 86% of colorectal cancer are in an immune ‘desert’ or immune-inflamed suppressed state, rendering traditional immune checkpoint inhibitors (ICIs) ineffective5. For colorectal cancer that has failed standard treatments, there are limited therapeutic options with short survival periods, representing a significant unmet clinical need6. IBI363, as a PD-1/IL-2α-bias bispecific fusion protein, has demonstrated robust antitumor efficacy in preclinical studies through the effective expansion of tumor-specific CD8⁺ T cells (TST cells). Its ability to block PD-1 and stimulate TST cells holds the potential to transform ‘cold’ tumors into ‘hot’ tumors. As a monotherapy, IBI363 achieves a median survival of 16.1 months in later-line treatments, which represents a significant improvement compared to the median survival of current standard therapies and also confirms its potential with a strong ‘tail effect’ as a PD1 plus cytokine bispecific immunotherapy. The combination of IBI363 with bevacizumab is still under continuous follow-up, having shown promising efficacy and tolerable safety, with unique efficacy characteristics particularly in the subgroup without liver metastasis. Overall, clinical data suggest that IBI363 combined with bevacizumab holds significant promise for colorectal cancer and warrants further exploration.”

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “On top of the preliminary data reported at 2024 ASCO and 2024 ESMO, we are presenting more updated follow-up data and combination therapy results of IBI363 at the ASCO Congress this year. From a comprehensive body of clinical evidence that includes ORR, PFS, OS, IBI363 demonstrated robust antitumor activity of both monotherapy and combination therapy in patients with advanced colorectal cancer who are non-MSI-H/dMMR. We are eyeing on long-term survival data from high dose in longer follow-up period. And the pivotal study of IBI363 targeting advanced CRC is in plan. Observing such results in the context of colorectal cancer, which is typically considered an immunologically ‘cold’ tumor, further highlights the broad development potential of IBI363. It offers hope for expanding into areas where immunotherapy has been less effective or even unresponsive.”

About IBI363 (First-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)

IBI363 is a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein independently developed by Innovent Biologics. It functions by both blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI363 is designed to maintain its affinity for IL-2Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm not only blocks PD-1 but also selectively delivers IL-2. This approach targets and activates tumor-specific T cells that express both PD-1 and IL-2α, leading to more precise and effective activation of this T cell subpopulation. IBI363 has demonstrated robust antitumor activity in various tumor-bearing pharmacological models, but also showed outstanding efficacy in PD-1 resistance and metastasis models. 

In response to urgent clinical needs, Innovent is conducting clinical studies in China, the United States and Australia to further explore the efficacy and safety of IBI363 in various tumor indications, including immune-resistant, cold tumors, and front-line treatments. The first pivotal trial of IBI363 was initiated in 2025 for unresectable locally advanced or metastatic mucosal or acral melanoma who have not received prior systemic therapy.

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the China NMPA, for the treatment of squamous non-small cell lung cancer and melanoma, respectively.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 15 products in the market. It has 3 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza®) and Selpercatinib (Retsevmo®) and Pirtobrutinib (Jaypirca®) were developed by Eli Lilly and Company.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Innovent, the Directors and the employees of Innovent assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

1. Dasari A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53.

2. Grothey A, et al. CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26;381(9863):303-12.

3. Mayer RJ, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. N Engl J Med. 2015 May 14;372(20):1909-1919. doi: 10.1056/NEJMoa1414325.

4. https://publications.iarc.fr/Databases/Iarc-Cancerbases/GLOBOCAN-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1.0-2012.

5. Huyghe N, et al. Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine. Cancers (Basel). 2022 Apr 29;14(9):2241.

6. O’Neil BH, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma. PLoS One. 2017 Dec 28;12(12):e0189848.

 

Hyundai Capital Australia Launches Kia Finance, Expanding its Finance Offerings to All Hyundai Motor Group Vehicles

SEOUL, South Korea, June 2, 2025 /PRNewswire/ — Hyundai Capital Services announced today that its Australian subsidiary Hyundai Capital Australia Pty. Ltd. (“HCAU” or the “Company”) launched Kia Finance and has commenced offering finance solutions for Kia customers in Australia.

Last year, HCAU commenced operations in the Australian market with the launch of Genesis Finance in October, followed by Hyundai Finance in November. With the introductions of Kia Finance, HCAU now delivers comprehensive automotive finance across all three Hyundai Motor Group brands – Hyundai, Genesis, and Kia. The company is committed to supporting vehicle sales through a broad range of business initiatives, offering tailored financial solutions such as retail finance for personal and business customers, alongside stable and reliable commercial funding for dealer partners.

A key offering from HCAU is the Guaranteed Future Value* (GFV) product, designed to make vehicle ownership more accessible through lower monthly repayments. HCAU secures the minimum resale value of the vehicle upfront, allowing the customer to defer this amount and make repayments based only on the balance. At the end of the loan term, customers have the flexibility to choose from the following options:

1. Trade-in: the vehicle’s value is used towards paying out the loan. If the trade-in value is higher than the GFV, the positive equity can be used towards a new vehicle.

2. Keep: pay the GFV amount to own the vehicle outright.

3. Return: return the vehicle with no further payments, provided the customer is not in default and the vehicle meets the agreed kilometre and fair wear and tear conditions.

Furthermore, HCAU offers competitive interest rates to customers, leveraging the strong global credit rating of the Hyundai Motor Group. In March, the Company received an initial credit rating of ‘A-‘ with a stable outlook from S&P Global Ratings (“S&P”), a notable achievement for a relatively new entrant to the market. This rating strengthens HCAU’s funding capacity in Australia, enabling it to continue delivering highly competitive interest rates to customers while supporting sustainable growth.

“With the launch of Kia Finance, HCAU is now able to offer a comprehensive range of automotive finance solutions for all Hyundai Motor Group vehicles in Australia,” said Donglim Shin, Chief Executive Officer of HCAU. He added, “HCAU will actively engage in a wide range of customer-centric marketing initiatives in partnership with Kia, Hyundai Motor and Genesis to ensure more customers can enjoy an exceptional ownership experience through our flexible finance options.

*The Guaranteed Future Value (GFV) is the minimum future value of your in-stock new or approved demo Hyundai, Genesis or Kia set out in your contract. At the end of the term, you can sell your car to us, and we will pay the GFV which will be put against your final payment, provided you’re not in default under your contract and subject to fair wear and tear requirements and agreed kilometres being met.

Finance is for approved applicants only. Terms, conditions, fees, charges and lending criteria applies. Hyundai Capital Australia Pty Ltd (ABN 42 611 226 316), Australian Credit Licence 554051.

BreastScreen Australia Density Reporting Rule is a Critical Step for Women says Volpara Health, the Leader in AI-assisted Breast Density Measurement

Volpara software is used to assess the breast density of more than 1 million Australian women
annually

WELLINGTON, New Zealand, June 2, 2025 /PRNewswire/ — Volpara Health, a Lunit a company and global leader in software for the early detection of breast cancer, today applauded the significant advancement in breast health management with BreastScreen Australia’s new position on breast density reporting. This new guidance recommends that all BreastScreen services in Australia provide breast density information to clients, enhancing awareness and understanding of this critical risk factor.

A Step Toward More Accurate and Personalised Breast Cancer Screening

Volpara’s Scorecard software is utilised to measure the breast density of over 1 million women annually across Australia, including in BreastScreen Victoria and BreastScreen South Australia. This comprehensive, AI-driven approach supports physicians in making consistent, objective assessments, helping to ensure that breast cancer risk is more accurately evaluated for each patient.

Volpara’s volumetric breast density assessment software, including its proprietary Volpara® TruDensity™ AI algorithm, provides consistent and precise breast density measurements. Cleared by the Therapeutic Goods Administration (TGA), FDA, Health Canada, and CE-marked in Europe, this technology has been validated in more than 400 scientific articles and research abstracts, underscoring its reliability and accuracy.

“We’ve been collaborating with leading clinicians and researchers worldwide for over a decade to make critical information about breast composition and its link to breast cancer more accessible,” said Craig Hadfield, CEO, Volpara Health. “The new guidelines from BreastScreen Australia validate our focus on applying tech and AI advancements to breast density and are a significant step forward in enhancing the experience and understanding for women and their healthcare providers. We encourage women to contact their local healthcare provider and ask how they assess breast density.”

Understanding Breast Density: A Critical Risk Factor

Breast density is an important factor in both breast cancer detection and risk assessment. It has been linked to an increased risk of developing breast cancer, while also making it more challenging to detect cancer through mammography. In Australia, approximately 40% of women have dense breasts, including 12% with extremely dense breasts. As breast density increases, the accuracy of mammography decreases.

Research published in Radiology reveals that mammography can miss up to 50% of cancers in women with the densest breast tissue. Since both dense breast tissue and tumours appear white on a mammogram, cancers are often concealed, potentially delaying diagnosis. Studies confirm that early detection rates improve significantly when women with very dense breasts receive additional imaging, such as ultrasound or MRI, as part of their regular screening regimen.

The Path Forward: Embracing Personalised Screening

Breast density information is also integrated into several risk models, which helps identify women at higher risk of breast cancer who may benefit from supplemental screening. Volpara Scorecard is the only commercial automated software validated for use in both the Tyrer-Cuzick 8 and CanRisk (BOADICEA) riskmodels, providing consistent and robust breast density measurements. With this new guidance, Volpara is poised to play an essential role in supporting risk assessment and personalised screening in Australia, further advancing the goal of improving outcomes for women.

The importance of personalised screening has also been recognised by other Australian health bodies, with Medicare recently introducing reimbursement for high-risk breast MRI screening based on Tyrer-Cuzick 8 or CanRisk risk assessment. This marks a growing recognition of the need for tailored breast cancer screening strategies that consider individual risk factors, including breast density.

About Volpara Health 

Volpara Health is on a mission to save families from cancer with AI-powered software that helps healthcare providers better understand cancer risk, guide personalized care decisions, and recommend additional imaging and interventions. Used in over 3,500 facilities by more than 9,500 technologists worldwide. Volpara’s software impacts nearly 18M patients, supports over 3.6M annual cancer risk assessments, and integrates seamlessly with electronic health records and imaging systems. Volpara helps radiologists quantify dense breast tissue with precision and technologists produce mammograms with optimal positioning, compression, and dose. Volpara software also streamlines operations to ease compliance and accreditation. Volpara, a Lunit company, is headquartered in Wellington, New Zealand, and has an office in Seattle. Volpara is the trusted partner of leading healthcare institutions globally. For more information, visit www.volparahealth.com.

Logo – https://laotiantimes.com/wp-content/uploads/2025/06/volpara_health_logo.jpg

Mérieux NutriSciences and AsureQuality Announce the Official Launch of Mérieux NutriSciences AQ (MNAQ) Joint Venture

CHICAGO and AUCKLAND, New Zealand, June 2, 2025 /PRNewswire/ — Mérieux NutriSciences, a global leader in food safety, quality, and sustainability, and AsureQuality, New Zealand’s premier food assurance provider, are pleased to announce the official launch of their joint venture, Mérieux NutriSciences AQ (MNAQ). The formation of MNAQ follows the successful completion of Mérieux NutriSciences’ acquisition of Bureau Veritas’ worldwide food testing activities, including its stake in the BVAQ joint ventures in Southeast Asia and Australia.

With the transaction having officially closed in Southeast Asia in January 2025 and now finalized in Australia as of May 31st 2025, MNAQ is fully established and poised to become a leading provider of food testing, assurance, and sustainability solutions in both regions.

Kim Ballinger, CEO of AsureQuality, highlighted the strategic significance of the partnership: 
“We are excited to officially launch MNAQ, reinforcing our commitment to delivering trusted food assurance services to the industry in Australia and Southeast Asia. This partnership with Mérieux NutriSciences strengthens our ability to support New Zealand exporters in key global markets and drive innovation in food safety and quality.”

Nicolas Cartier, CEO of Mérieux NutriSciences, echoed this enthusiasm: 
“The completion of this joint venture marks an important milestone in our global growth strategy and purpose. By combining our scientific expertise and deep industry knowledge, and leveraging a team of over 700 talented employees, MNAQ is uniquely positioned to serve our customers across the food value chain with high-value, science-based solutions. Together with our partners at AsureQuality, we are proud to contribute to safer, more sustainable food systems across Southeast Asia and Australia, and beyond.”

As MNAQ moves forward, it will focus on delivering innovative, science-driven solutions to support food industry players in the region. With a strong foundation built on technical excellence and a shared commitment to food integrity and customer-centricity, the joint venture aims to set new benchmarks for food assurance in Southeast Asia and Australia.

About Mérieux NutriSciences:
Mérieux NutriSciences leverages over 50 years of scientific and entrepreneurial expertise to answer food industry needs. Today’s global challenges transform the way food is produced, marketed and consumed, which is why we know our clients need more than reliable analytical results; they need practical and innovative solutions that will contribute to make food systems safer, healthier and more sustainable. Present worldwide, we have more than 140 accredited laboratories and a team of over 10,000 talented employees. We strongly believe that together, we can create solutions to offer our planet: BETTER FOOD. BETTER HEALTH. BETTER WORLD. www.merieuxnutrisciences.com 

About AsureQuality:
AsureQuality is a New Zealand government-owned entity providing integrated, end-to-end food assurance and services to the food and primary production sectors. With a scientific and agricultural heritage spanning 150 years, AsureQuality has built a trusted reputation for delivering expert services and value across the entire food supply chain. www.asurequality.com 

Photo – https://laotiantimes.com/wp-content/uploads/2025/06/joint_venture-1.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/06/mnaq_logo-1.jpg

Media contacts:

MÉRIEUX NUTRISCIENCES

 

media@mxns.com

ASUREQUALITY

 

marketing@asurequality.com 

 

 

Mérieux NutriSciences and AsureQuality Announce the Official Launch of Mérieux NutriSciences AQ (MNAQ) Joint Venture
Mérieux NutriSciences and AsureQuality Announce the Official Launch of Mérieux NutriSciences AQ (MNAQ) Joint Venture